Carbon Medical Technologies, Inc., a St. Paul-based company developing implantable medical devices using a proprietary pyrolytic carbon-coating technology, has appointed a new President and CEO for the first time in three decades. Stephanie Kent is a transformative leader with experience developing strategies to support new and critical business opportunities. Prior to joining Carbon Medical, Stephanie served in a number of different capacities at Target Corporation. Most recently, she was responsible for developing and leading integration strategies for Target’s acquisitions.
“We are extremely pleased to welcome Stephanie and believe her experience will complement the expertise of the existing team,” said Tim Lawin, Chairman of the Board of Directors for Carbon Medical Technologies. “Under Stephanie’s leadership, we are confident in the company’s ability to unlock new business opportunities.”
“I am honored to join the Carbon Medical Technologies team and I feel fortunate to be a part of an organization that seeks to develop best-in-class products that improve lives throughout the world,” said Stephanie. “Carbon Medical Technologies was founded in 1994 and has been operating successfully for over 25 years. I’m excited to reintroduce patients, providers and partners to the many products and services available, and I look forward to leading the company through the next period of growth.”
As part of that reintroduction effort, the company recently launched its new website: www.carbonmed.com. “We are excited to announce the launch of our newly designed website” Stephanie said. “We sought to make the new website faster and easier to navigate, while providing current and prospective customers with useful information about our products and services.”
About Carbon Medical Technologies, Inc.
Carbon Medical Technologies, Inc. (CMT) is a privately held company formed in 1994 to design, develop, and manufacture permanent human implantable products utilizing pyrolytic carbon. Carbon is a naturally occurring element in the human body. As a result, pyrolytic carbon is not recognized by the human body as foreign, thus rendering it ideal as a permanent implant material. CMT operates a fully functional pyrolytic carbon coating facility, one of five known to exist in the world.
CMT has developed multiple FDA approved and CE Marked products and utilizes major medical device companies to market its products throughout the world. Currently, the pyrolytic carbon coating technology is incorporated into BiomarC implantable tissue markers developed for biopsy site marking and the BiomarC fiducial marker product line for radiation therapy treatment planning. CMT products also include a pyrolytic carbon based injectable bulking agent called Durasphere, which is used for the treatment of stress urinary incontinence in women, and additional indications outside of the US.
CMT also provides product development, contract manufacturing, and regulatory consulting for medical device companies. CMT is a medical device manufacturer with ISO 13485 certified and cGMP compliant quality systems. CMT maintains three different sterilization method validations and does final product assembly and packaging in an ISO Class 7 clean room environment.
